
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Coupang, you need to believe its heavy investment in logistics, AI and new markets can eventually justify current losses and convert strong revenue into durable profits. The latest results, with EPS swinging back into negative territory despite higher sales, keep the near term focus squarely on whether management can rein in costs. That makes the key catalyst now a clear path to margin improvement, while the biggest risk is prolonged cash burn in newer initiatives like Taiwan.
Against this backdrop, Coupang’s large-scale share repurchase program stands out. Since early 2025, the company has bought back over 52 million shares for roughly US$1,093.8 million under its expanded US$2,000 million authorization. This capital return may appeal to some investors, but it sits uncomfortably beside rising net losses, sharpening the question of whether buybacks are being funded from a business that is not yet consistently profitable.
Yet beneath this investment story, there is a less obvious risk around sustained losses in early stage markets that investors should be aware of...
Read the full narrative on Coupang (it's free!)
Coupang's narrative projects $47.4 billion revenue and $1.3 billion earnings by 2029. This requires 10.5% yearly revenue growth and an earnings increase of about $1.5 billion from -$165.0 million today.
Uncover how Coupang's forecasts yield a $25.83 fair value, a 56% upside to its current price.
Some of the lowest ranked analysts were already cautious, assuming revenue of about US$46.1 billion and earnings of only US$910.2 million by 2029, so this setback could further challenge those more pessimistic views and is a reminder that your own take on Coupang’s risks and potential might differ significantly from theirs.
Explore 7 other fair value estimates on Coupang - why the stock might be worth over 2x more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com